Antituberculosis drug- induced hepatitis, an unpredictable phenotype

M. da Silva Alcobia (Coimbra, Portugal), L. M Nogueira (Coimbra, Portugal), B. Oliveiros (Coimbra, Portugal), C. Robalo Cordeiro (Coimbra, Portugal), H. C Silva (Coimbra, Portugal)

Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Session: Extra-pulmonary tuberculosis and comorbidities
Session type: Thematic Poster
Number: 2986
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. da Silva Alcobia (Coimbra, Portugal), L. M Nogueira (Coimbra, Portugal), B. Oliveiros (Coimbra, Portugal), C. Robalo Cordeiro (Coimbra, Portugal), H. C Silva (Coimbra, Portugal). Antituberculosis drug- induced hepatitis, an unpredictable phenotype. 2986

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010

Identifying genetic susceptibility to isoniazid- induced hepatitis
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013


Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity
Source: International Congress 2015 – Screening strategies in TB
Year: 2015

Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy
Source: Eur Respir J 2009; 33: 1518-1519
Year: 2009


The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001

Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021


Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis
Source: ISSN=ISSN 1810-6838, ISBN=, page=69
Year: 2007

The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity
Source: Eur Respir J 2006; 28: Suppl. 50, 505s
Year: 2006

Fulminant hepatitis during antituberculosis chemotherapy: five case reports
Source: Eur Respir J 2005; 26: Suppl. 49, 645s
Year: 2005

Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB)
Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Year: 2007


Sarcoidosis associated with interferon-α therapy for chronic hepatitis C
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006

Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?
Source: Eur Respir J 2007; 29: 347-351
Year: 2007



Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019

Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010

Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020


Antituberculotic drug-induced medicamentous liver damages
Source: Eur Respir J 2004; 24: Suppl. 48, 51s
Year: 2004

Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis
Source: Eur Respir J 2006; 28: Suppl. 50, 13s
Year: 2006

Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010

Do different vaccination regimens for BCG and hepatitis B affect the development of allergic disorders in early childhood?
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007


Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007